Kyverna Therapeutics (KYTX) awards stock options and RSUs to officer Naji Gehchan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. reported that officer Naji Gehchan received new equity awards as part of compensation. He was granted stock options for 105,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. These options vest over time, with one-fourth vesting on March 13, 2027 and the remaining shares vesting in equal monthly installments thereafter, subject to continued service. He also received a restricted stock unit award covering 18,000 shares of common stock, with one-fourth vesting on March 13, 2027 and the rest vesting in equal annual installments, also subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GEHCHAN NAJI

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	105,000	$0.00	--
Grant/Award	Common Stock	18,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 105,000 shares (Direct); Common Stock — 18,000 shares (Direct)

Footnotes (1)

Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/17/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEHCHAN NAJI

(Last)

(First)

(Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE

94608

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/13/2026		A		18,000⁽¹⁾	A	$0	18,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.95	03/13/2026		A		105,000		⁽²⁾	03/13/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney Chief Medical & Development Officer

	By: /s/ Marc Grasso, as Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Naji Gehchan receive from Kyverna Therapeutics (KYTX)?

Naji Gehchan received stock options for 105,000 Kyverna Therapeutics shares and a restricted stock unit award covering 18,000 common shares. Both awards are compensation grants that vest over several years, contingent on his continued service with the company through each vesting date.

What are the key terms of Naji Gehchan’s new stock options at Kyverna Therapeutics (KYTX)?

The new stock options cover 105,000 Kyverna Therapeutics common shares at a fixed exercise price of $8.95 per share and expire on March 13, 2036. One-fourth of the option vests on March 13, 2027, with the remainder vesting monthly thereafter, subject to continued service.

How do Naji Gehchan’s restricted stock units (RSUs) at Kyverna Therapeutics (KYTX) vest?

The restricted stock unit award covers 18,000 Kyverna Therapeutics common shares. One-fourth of the RSUs vest on March 13, 2027, and the remaining three-fourths vest in equal installments on each subsequent one-year anniversary, assuming he continues serving the company through each vesting date.

Are Naji Gehchan’s Form 4 transactions in Kyverna Therapeutics (KYTX) open-market buys or compensation grants?

The Form 4 shows compensation-related grants, not open-market purchases. Both the 105,000 stock options and 18,000 restricted stock units were acquired at a price of $0.00 per share, reflecting awards granted by Kyverna rather than shares bought on the market.

What is Naji Gehchan’s position in Kyverna Therapeutics (KYTX) after these equity awards?

After the reported awards, Naji Gehchan directly holds stock options covering 105,000 Kyverna common shares and a separate restricted stock unit award covering 18,000 shares. The filing reports 105,000 option-based shares and 18,000 shares of common stock as his post-transaction holdings for these grants.

What conditions must be met for Naji Gehchan’s Kyverna (KYTX) equity awards to vest?

Both the stock options and restricted stock units require Naji Gehchan’s continuous service with Kyverna through each vesting date. If he remains in service, portions vest starting March 13, 2027, with remaining shares vesting monthly or annually according to the specific schedules.